Oramed Pharmaceuticals (ORMP) Other Non-Current Assets (2016 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Other Non-Current Assets came in at $46000.0 in Q1 2026, up 2200.0% YoY from $2000.0 in Q1 2025, and up 4.55% on a QoQ basis from $44000.0 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Other Non-Current Assets (2016 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 10 years of Other Non-Current Assets data on file, last reported at $46000.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 2200.0% year-over-year to $46000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46000.0 (up 2200.0% YoY) and the FY2025 annual result came in at $44000.0, up 2100.0% from the prior year.
- Other Non-Current Assets grew to $46000.0 in Q1 2026, from $44000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $111.5 million in Q4 2022 to a low of $2000.0 in Q2 2024.
- A 5-year average of $8.6 million and a median of $7000.0 in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets slumped 99.98% — and 2026, when it jumped 2200.0%.
- Tracing ORMP's Other Non-Current Assets over 5 years: stood at $111.5 million in 2022, then tumbled by 99.98% to $27000.0 in 2023, then sank by 92.59% to $2000.0 in 2024, then soared by 2100.0% to $44000.0 in 2025, then increased by 4.55% to $46000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $46000.0 (Q1 2026), $44000.0 (Q4 2025), and $40000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | 49,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49,000.00 |
| Mar 31, 2026 | 46,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Sep 30, 2025 | 40,000.00 |
| Jun 30, 2025 | 38,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Dec 31, 2022 | 111.51 Mn |
| Aug 31, 2021 | 11.04 Mn |
| Aug 31, 2020 | 11.06 Mn |
| Aug 31, 2018 | 13.54 Mn |
| Nov 30, 2017 | 17.78 Mn |
| Aug 31, 2017 | 16.23 Mn |
| Aug 31, 2016 | 11.04 Mn |